Abstract:e12614 Background: Tumor response to neoadjuvant therapy (NAT) in patients with breast cancer is related to perfusion in the tumor microenvironment and surrounding tissue. Direct and indirect measures of microvascular (MV) permeability could improve the ability to predict short- and long-term patient outcomes. Detection and quantification of circulating tumor DNA (ctDNA) is one such measurement that depends on microvasculature and has been shown to strongly correlate with both response to therapy and overall prognosis in a wide range of cancers. We hypothesized that a combination of ctDNA and numerical computations of MV permeability using pretreatment dynamic contrast-enhanced (DCE) MRI images (MV maps) can predict patient response to NAT and long-term survival outcomes. Here, we show how MV maps — computed from standard-of-care (SOC) imaging — improve upon ctDNA measurements in predicting pathologic complete response (pCR) following NAT as well as distant recurrence free survival (DRFS). Methods: DCE-MRIs were obtained for a sub-sample of I-SPY2 patients (n = 81) whose ctDNA levels were previously reported (Magbanua et al 2021). Tumors were segmented from pretreatment images by a convolutional neural network with manual verification. MV maps were computed using a Tofts-like model to describe the transfer kinetics between microvasculature and extracellular extravascular space. Microvasculature parameters (MVPs), such as median and skewness, were extracted from MV maps to describe the distribution of kinetic parameters in the intra- and peritumoral regions. Logistic regression was used to predict pCR with leave-one-out cross validation. Univariate Cox models were used to stratify DRFS. Results: MVPs exhibited a moderate correlation with pretreatment ctDNA levels (Spearman rho = -0.26; p = 0.018) and with pCR status in this cohort (rho = 0.25; p = 0.026). In a series of logistic regression models, a combination of SOC clinical features and ctDNA levels correctly classified 23% of true pCRs, with an F1 score of 0.58. This predictive power increased when informed by MV maps; 45% of true pCRs were identified after the addition of MVPs, and the F1 score increased to 0.68. In univariate Cox models, 24 MVPs significantly stratified DRFS (p < 0.05) when uncorrected for multiple hypothesis testing bias. The top MVP carried a hazard ratio 3.8 (95%CI 1.6 - 9.0) compared to 11.9 (95%CI 2.7 - 53.6) for ctDNA levels. Conclusions: DCE-MRI-derived kinetic features are calculated from SOC images with no additional clinical intervention. We found that MVPs substantially improve pCR prediction when added to models trained on ctDNA levels and clinical features. ctDNA levels and MVPs were predictive of DRFS to differing degrees of confidence. Although further validation in larger datasets is needed, this exploratory analysis uncovered a promising role for MV maps in predicting response to NAT as well as patient outcomes.

Perfusion and Permeability MRI Predicts Future Cavernous Angioma Hemorrhage and Growth

Abstract P36: Lesional Perfusion and Permeability Are Diagnostic and Prognostic Biomarkers of Cavernous Angioma With Symptomatic Hemorrhage

Abstract TP12: Changes in Plasma Metabolites Reflect Lesional Iron Content and Permeability Imaging as Monitoring Biomarkers of Hemorrhage in Cavernous Angiomas

Abstract WP17: Plasma Proteins In Correlation With Lesional Iron Content And Permeability Imaging In Clinical Trial Of Cavernous Angioma With Symptomatic Hemorrhage

Quantitative image signature and machine learning-based prediction of outcomes in cerebral cavernous malformations

Abstract 123: In Vivo Permeability Of The Aging Brain With Cerebral Microbleeds

Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part II: Biomarkers and Trial Modeling

A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH)

Understanding the Importance of Blood-Brain Barrier Alterations in Brain Arteriovenous Malformations and Implications for Treatment: A Dynamic Contrast-Enhanced-MRI-Based Prospective Study

Dynamic Permeability and Quantitative Susceptibility

Abstract TMP1: Multi-omic Biomarker Development In A Mendelian Neurovascular Disease, Cavernous Angioma

Predictors of future haemorrhage from cerebral cavernous malformations: a retrospective cohort study

Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Analysis of Microvascular Permeability in Peritumor Brain Edema of Fibrous Meningiomas

Dynamic Contrast-Enhanced MRI Perfusion Parameters Are Imaging Biomarkers for Angiogenesis in Lung Cancer

Feasibility of FDCT Early Brain Parenchymal Blood Volume Maps in Predicting Short-Term Prognosis in Patients with Aneurysmal Subarachnoid Hemorrhage.

Multidelay MR Arterial Spin Labeling Perfusion Map for the Prediction of Cerebral Hyperperfusion After Carotid Endarterectomy

DCE-MRI-derived microvasculature mapping and outcome prediction in patients with breast cancer.

Prognostic Prediction Based on Dynamic Contrast-Enhanced MRI and Dynamic Susceptibility Contrast-Enhanced MRI Parameters from Non-Enhancing, T2-High-Signal-Intensity Lesions in Patients with Glioblastoma

Circulating Blood Prognostic Biomarker Signatures for Hemorrhagic Cerebral Cavernous Malformations (CCMs)

Proteomics on human cerebral cavernous malformations reveals novel biomarkers in neurovascular dysfunction for the disease pathology

Prognostic Value of Angiographic Based Quantitative Flow Ratio and Anatomic Features in Intracranial Atherosclerotic Stenosis